CNO Financial Group, Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. CNO Financial Group, Inc. is a holding company for insurance subsidiaries developing, marketing, and administering health insurance, annuity, and individual life insurance products. The company serves middle-income pre-retiree and retired Americans through exclusive agents, independent producers, and direct marketing channels. Notably, the company completed its exit from the fee services business within its Worksite Division as of June 30, 2026, to focus on core insurance operations.
Key Financial Metrics
| Metric (Dollars in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $1,285.2 | $1,151.5 | $2,314.8 | $2,155.6 |
| Net Income | $125.9 | $91.8 | $163.6 | $113.3 |
| Diluted EPS | $1.33 | $0.91 | $1.71 | $1.11 |
| Net Operating Income (Non-GAAP) | $119.5 | $87.5 | $220.8 | $168.6 |
| Total Assets | $39,861.2 | $38,790.6 | - | - |
| Total Liabilities | $37,269.6 | $36,152.4 | - | - |
| Shareholders' Equity | $2,591.6 | $2,638.2 | - | - |
| Investment Borrowings | $2,941.7 | $2,441.7 | - | - |
| Cash & Equivalents (Unrestricted) | $1,289.7 | $956.1 | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.6% year-over-year in Q2 2026, driven by higher insurance policy income and net investment income.
- Profitability: Net income rose 37.1% in Q2 2026 compared to Q2 2025. Net operating income increased 36.6% to $119.5 million.
- Investment Portfolio: Total investments grew to $30.7 billion. The company recognized net realized investment losses of $14.7 million in Q2 2026, primarily due to sales of lower-yielding corporate securities to reinvest in higher-yielding assets.
- Debt Levels: Investment borrowings increased by approximately $500 million to $2.94 billion, utilized to purchase matched variable-rate fixed maturity securities.
- Segment Performance:
- Annuity Margin: Increased to $60.6 million (Q2 2026) from $54.8 million (Q2 2025), driven by spread income growth.
- Health Margin: Increased to $147.2 million, aided by favorable morbidity and rate increases in Medicare supplement products.
- Life Margin: Increased to $71.2 million, reflecting lower advertising expenses and lower mortality.
Guidance, Outlook, and Risks
- 2026 Guidance Update: Management raised full-year operating earnings per diluted share guidance to $4.60 - $4.80 (previously $4.25 - $4.45). The expense ratio guidance was narrowed to 18.8% - 19.0%.
- Tax Rate: The effective tax rate assumption was lowered to approximately 21.5% due to favorable non-recurring tax deductions.
- Capital Targets: The company expects to maintain a consolidated Risk-Based Capital (RBC) ratio between 360% and 390% and a debt-to-total capital ratio (excluding AOCI) between 25% and 28%.
- TechMod Initiative: A three-year technology modernization project is underway, with expected costs of approximately $76 million in 2026. These costs are excluded from operating income.
- Risks: Key risks include interest rate volatility, investment credit losses, regulatory changes, and the outcome of pending litigation (specifically the Burnett v. Conseco Life case, where a bench trial on alter ego liability is pending).
Investor Verification Checklist
- Investment Credit Quality: Verify the composition of the $41.5 million allowance for credit losses and the $2.1 billion in gross unrealized losses on fixed maturities.
- Fee Services Exit: Confirm the financial impact of the completed exit from the Worksite Division fee services business on future revenue streams.
- Technology Costs: Monitor the $23.4 million in TechMod expenses incurred YTD 2026 and their impact on non-operating income.
- Regulatory Capital: Review the consolidated statutory RBC ratio of 377% to ensure it remains within the targeted 360%-390% range.
- Share Repurchases: Note the $120 million spent on share repurchases YTD 2026, with $300.4 million of authority remaining.